Senda Biosciences

Senda, a Flagship Pioneering Company, is a biotech company on a mission to bring life-changing treatments to patients by using nature’s codes to fully program medicines, potentially unlocking new levels of speed, breadth, and productivity in the development of advanced therapies.

Senda systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines.

Senda was founded in 2017 by Flagship Pioneering. The company is headquartered in Cambridge, Massachusetts.

 

Senda's proprietary platform includes an mRNA engine and the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life—accessing the entire code provided by nature required to program cells.

 

Senda uses its platform to develop a new class of SendRNA™ medicines for infectious, genetic, metabolic, and autoimmune diseases, as well as oncology and powering new frontiers for mRNA therapeutics and vaccines and gene-editing and protein-based therapies.

 

Senda has also generated preclinical data showing they can engineer bacteria-derived therapeutics that enable tunable, antigen-specific antibody and T cell responses.

 

Senda is backed by Flagship Pioneering, Longevity Vision Fund, Terra Magnum Capital Partners, Mayo Clinic, Alexandria Venture Investments, Qatar Investment Authority, Samsung Life Science Fund, Bluwave Capital, Stage 1 Ventures, and tohers. The company completed a $123M Series C round on Aug 16, 2022. This brings Senda's total funding to $266M to date.

 

 

  • Year founded: 2017
  • Funding Info: $266M over 4 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses